D
Damien Kee
Researcher at Peter MacCallum Cancer Centre
Publications - 46
Citations - 3544
Damien Kee is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 14, co-authored 37 publications receiving 2994 citations. Previous affiliations of Damien Kee include Walter and Eliza Hall Institute of Medical Research & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva,Adina Vultur,John T. Lee,Rajasekharan Somasundaram,Mizuho Fukunaga-Kalabis,Angela K. Cipolla,Bradley Wubbenhorst,Xiaowei Xu,Phyllis A. Gimotty,Damien Kee,Ademi Santiago-Walker,Richard Letrero,Kurt D'Andrea,Anitha Pushparajan,James Hayden,Kimberly Dahlman Brown,Sylvie Laquerre,Grant A. McArthur,Jeffrey A. Sosman,Katherine L. Nathanson,Meenhard Herlyn +20 more
TL;DR: Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF- 1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.
Journal ArticleDOI
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Fei Su,Amaya Viros,Carla Milagre,Kerstin Trunzer,Gideon Bollag,Olivia Spleiss,Jorge S. Reis-Filho,Xiangju Kong,Richard C. Koya,Keith T. Flaherty,Paul B. Chapman,Min Jung Kim,Robert Hayward,Matthew J. Martin,Hong Yang,Qiongqing Wang,Holly Hilton,Julie S. Hang,Johannes Noe,Maryou B K Lambros,Felipe C. Geyer,Nathalie Dhomen,Ion Niculescu-Duvaz,Alfonso Zambon,Dan Niculescu-Duvaz,Natasha Preece,Lidia Robert,Nicholas Otte,Stephen Mok,Damien Kee,Yan Ma,Chao Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Hoa Nguyen,Mark M. Kockx,Luc Andries,Brian Lestini,K. B. Nolop,Richard J. Lee,Andrew K. Joe,James L. Troy,Rene Gonzalez,Thomas E. Hutson,Igor Puzanov,Bartosz Chmielowski,Caroline J. Springer,Grant A. McArthur,Jeffrey A. Sosman,Roger S. Lo,Antoni Ribas,Richard Marais +52 more
TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.
Journal ArticleDOI
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer,Damien Kee,Damien Kee,Piotr Dziunycz,Antje Sucker,Nyam Kamsu-Kom,Robert T. Jones,Christine Roden,Clinton J. Chalk,Kristin G. Ardlie,Emanuele Palescandolo,Adriano Piris,Laura E. MacConaill,Laura E. MacConaill,Caroline Robert,Günther F.L. Hofbauer,Grant A. McArthur,Dirk Schadendorf,Levi A. Garraway +18 more
TL;DR: Squamous cell tumors from patients treated with an RAF inhibitor have a distinct mutational profile that supports a mechanism of therapy-induced tumorigenesis in RAS-primed cells, and Conceivably, cotargeting of MEK together with RAF may reduce or prevent formation of these tumors.
Journal ArticleDOI
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas,Rene Gonzalez,Anna C. Pavlick,Omid Hamid,Thomas F. Gajewski,Adil Daud,Lawrence E. Flaherty,Theodore F. Logan,Bartosz Chmielowski,Karl D. Lewis,Damien Kee,Peter D. Boasberg,Ming Yin,Iris T. Chan,Luna Musib,Nicholas Choong,Igor Puzanov,Grant A. McArthur +17 more
TL;DR: The combination of vemurafenib and cobimetinib was safe and tolerable when administered at the respective maximum tolerated doses, and has promising antitumour activity.
Journal ArticleDOI
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
Oliver Klein,Damien Kee,Adnan Nagrial,Ben Markman,Craig Underhill,Michael Michael,Louise Jackett,Caroline Lum,Andreas Behren,Jodie Palmer,Niall C. Tebbutt,Matteo S. Carlino,Jonathan Cebon +12 more
TL;DR: This subgroup analysis of a phase 2 clinical trial found that combination immunotherapy with nivolumab and ipilimumab was associated with substantial positive outcomes patients with advanced biliary tract cancers.